Kovitz Investment Group Partners
GALT icon

Kovitz Investment Group Partners’s Galectin Therapeutics GALT Stock Holding History

Kovitz Investment Group Partners’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,315
Closed -$22.3K – 1374
2025
Q1 		$22.3K Hold
18,315
– – ﹤0.01% 1239
2024
Q4 		$23.6K Sell
18,315
-24,225
-57% -$58.1K ﹤0.01% 1224
2024
Q3 		$117K Buy
+42,540
New +$104K ﹤0.01% 975

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kovitz Investment Group Partners's GALT Position: Q2 2025 in Review

Kovitz Investment Group Partners sold out of Galectin Therapeutics (GALT) in Q2 2025, closing a stake of 18,315 shares — an estimated $22.3K sold.

Kovitz Investment Group Partners first reported a position in GALT in Q3 2024 and held it in 3 quarters. The position peaked at $117K in Q3 2024. 86 funds tracked by Wall St. Rank hold GALT as of Q2 2025.

  • Kovitz Investment Group Partners reported no remaining Galectin Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Kovitz Investment Group Partners sold 18,315 Galectin Therapeutics shares in Q2 2025, an estimated $22.3K.
  • Kovitz Investment Group Partners first reported a position in Galectin Therapeutics in Q3 2024 and held it in 3 quarters.
  • Kovitz Investment Group Partners's Galectin Therapeutics position peaked at $117K in Q3 2024.
  • 86 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2025.

Based on Kovitz Investment Group Partners's 13F filing for Q2 2025, filed 14 Aug 2025.